{"title":"On F<sub>β</sub> -score for medical diagnostics tests of binary diseases: proposing new measures of accuracy.","authors":"Marwan Alsharman, Hani Samawi, Jing Kersey, Divine Wanduku","doi":"10.1080/10543406.2025.2469866","DOIUrl":null,"url":null,"abstract":"<p><p>Accurate differentiation between health states - diseased or non-diseased - is essential in clinical diagnostics. Optimal cut-off points, or thresholds used to classify test results, are crucial for precise diagnoses. This work introduces the Harmonic Mean of F-score and inverse F-score (<i>HF</i>), a novel metric for a balanced assessment of diagnostic accuracy. <i>HF</i> integrates Specificity (<i>Sp</i>) and Negative Predictive Value (NPV) into the Negative F-score (<i>NF</i><sub><i>γ</i></sub>), ensuring a comprehensive evaluation of true negatives and negative test reliability. Prioritizing both true positives and true negatives, <i>HF</i> was used in optimal cut-off point estimation under binary disease classification. Simulation results revealed that the <i>HF</i> measure performed well, often surpassing established methods in specific settings. The <i>HF</i> measure and cut-off point selection criterion were applied to real-life data, showcasing its ability to provide a balanced evaluation of diagnostic accuracy. The <i>HF</i> measure frequently outperformed traditional metrics. The <i>HF</i> metric's flexibility, allowing parameter adjustments to accommodate diverse scenarios, enables researchers and clinicians to tailor its emphasis on specific aspects of diagnostic performance depending on the context.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1-27"},"PeriodicalIF":1.2000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2025.2469866","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Accurate differentiation between health states - diseased or non-diseased - is essential in clinical diagnostics. Optimal cut-off points, or thresholds used to classify test results, are crucial for precise diagnoses. This work introduces the Harmonic Mean of F-score and inverse F-score (HF), a novel metric for a balanced assessment of diagnostic accuracy. HF integrates Specificity (Sp) and Negative Predictive Value (NPV) into the Negative F-score (NFγ), ensuring a comprehensive evaluation of true negatives and negative test reliability. Prioritizing both true positives and true negatives, HF was used in optimal cut-off point estimation under binary disease classification. Simulation results revealed that the HF measure performed well, often surpassing established methods in specific settings. The HF measure and cut-off point selection criterion were applied to real-life data, showcasing its ability to provide a balanced evaluation of diagnostic accuracy. The HF measure frequently outperformed traditional metrics. The HF metric's flexibility, allowing parameter adjustments to accommodate diverse scenarios, enables researchers and clinicians to tailor its emphasis on specific aspects of diagnostic performance depending on the context.
期刊介绍:
The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers:
Drug, device, and biological research and development;
Drug screening and drug design;
Assessment of pharmacological activity;
Pharmaceutical formulation and scale-up;
Preclinical safety assessment;
Bioavailability, bioequivalence, and pharmacokinetics;
Phase, I, II, and III clinical development including complex innovative designs;
Premarket approval assessment of clinical safety;
Postmarketing surveillance;
Big data and artificial intelligence and applications.